Brief Presentation Pharma Company Profile by dho13483

VIEWS: 92 PAGES: 13

Brief Presentation Pharma Company Profile document sample

More Info
									Assignment Brief for the position of
Director, New Targets Biology
                for
         UCB Pharma
             AQ1847



                                                Prepared by:

                                            Dr Grant Coren
                                          Astralis Group Plc
                                           New Barnes Mill
                                           Cotton Mill Lane
                                                   St Albans
                                               Hertfordshire
                                                   AL1 2HA


                                  Tel: + 44 (0) 1727 867 070
                               grant.coren@astralisgroup.com

                                               October 2008
The Organisation

Headquartered in Brussels (Belgium), UCB is a global biopharmaceutical company
that combines the infrastructure and expertise of a traditional Pharma company with
the speed, innovation and entrepreneurship of a biotechnology company.


  UCB is passionate about enabling families with severe diseases to
                   enjoy normal, everyday lives.
         A global pharmaceutical company focused in severe diseases with operations
         in more than 40 countries and global revenues in excess of €3.6 billion in
         2007.
         A leader in epilepsy and allergy with 14 large and small molecules in their
         clinical pipeline spanning 16 diseases, from Crohn’s and Parkinson’s to
         multiple sclerosis.
         A leader in antibody research supported by propriety chemistry and over 30
         major R&D partners.

Vision

To build a global biopharmaceutical leader based on the unique blending of
innovation, entrepreneurship and proven experience, bringing to specialists first, new
medicines to treat patients suffering from severe diseases.

UCB’s vision is to be “the next generation biopharma leader” – through the
development of scientific and technological advances to create new opportunities to
address the complex interconnections of severe diseases with greater efficiency.

This can only be achieved by:

         Connecting science in new ways
         Connecting people
         Connecting patients

Values

         Passion and Performance                     Integrity and Quality
         Care                                        Innovation
         Accountability                              Focus and "Act Now"
         Entrepreneurship
With the acquisition of Celltech in 2004 and Schwarz Pharma in 2007 and the
divestment of the Chemicals division in 2005, UCB has successfully transformed
itself from a hybrid pharma and chemical company into a global next generation
biopharma leader. UCB is one of the world's top biopharma players investing more
than 25% of its sales in R&D.

Its unique approach in integrating biology and chemistry allows UCB’s discovery,
research and development scientists to gain much deeper insights into disease
pathways and produce more potent and cost-effective therapeutic solutions. The fruits
of this approach can be seen in UCB's very rich R&D pipeline with more than 10
molecules in development.

The results are a powerful drug-discovery platform and the ability to target specialists
in selected severe-disease areas with a relatively small sales force.

Their focus centres around two key therapeutic areas:

         Central Nervous System
         Inflammation


UCB’s strategy for continued success includes:


         Combining the very best biology and chemistry to achieve major
         breakthroughs
         Integrating expertise in large, antibody based molecules with small,
         chemically derived molecules
         Partnering with leaders in the pharmaceutical industry
         Leveraging their global scale and intellectual capital
Commercial growth and success

UCB is a highly successful Biopharmaceutical company, with net sales of €3.2 billion
euro in 2007.

Keppra (levetiracetam) reinforced its position as the leading treatment for epilepsy in
the US and Europe with a 35% rise in global sales to €1,026 million – Keppra is
currently manufactured in Braine l’Alleud. Keppra remains the market leader in the
United States and Europe

Zyrtec (cetirizine) still performed extremely well in the USA with an impressive
growth and remains the market leader.

Xyzal (levocetirizine) also increased net sales for the year, further consolidating
UCB’s position as a global leader in allergy therapeutics. It is approaching market
leadership in Europe and has recently been launched, under a co-marketing agreement
in the United States.

Key Facts and Figures

       UCB currently employs over 12,000 people
       Company operations exist in more than 40 countries worldwide
       2007 net sales were distributed over the USA (46%), Europe (42%), Rest of
       the World (12%).
       Revenue in excess of €3.6 billion in 2007
       Net sales worth greater than €32 billion in 84 countries in 2007
       Healthy pipeline with 14 molecules in clinical development
       Global R&D, marketing and sales platform
       Over 30 R&D and commercial partners

The Research capability is global and centred around two centres of excellence in
Europe: Braine-l'Alleud (Belgium) is focused on the central nervous system, and
Slough (UK) covering antibodies and inflammation.

The leading Development activities are organised on a global scale with sites in
Atlanta (USA), Brain-l’Alleud (Belgium), Monheim (Germany), Research Triangle
Park (USA), Slough (UK) and Tokyo (Japan).
UCB’s global commercial operations are structured in three business units: Central
Nervous System, Inflammation and Primary Care. These are responsible for
marketing, medical information and distribution of pharmaceuticals originating from
UCB’s research and development in the fields of neurology, allergic/respiratory
diseases as well as other primary care diseases. A strong international network of
Medical Affairs teams supports these activities.

A significant advance in quality and efficiency to world class standards has also been
achieved through several initiatives. This has included technical innovations within
manufacturing processes, thereby reducing costs whilst at the same time ensuring the
highest quality and the ability to meet increased demands without any interruption in
supply.

UCB's main manufacturing sites are located in Braine-l’Alleud (Belgium), Bulle
(Switzerland), Pianezza (Italy) Rochester (USA) , Tokyo (Japan), Vapi (India) and
Schwarz Pharma have additional sites in USA, Ireland, China and Germany.


       The company’s major pharmaceutical successes include:

        Keppra (levetiracetam), an innovative antiepileptic drug with a high efficacy
        and an excellent tolerability profile.
        Xyzal (levocetirizine), a leading antihistamine with high activity in perennial
        and seasonal allergic rhinitis and chronic idiopathic urticaria.
        Zyrtec (cetirizine), a blockbuster antihistamine with high activity in perennial
        and seasonal allergic rhinitis and chronic idiopathic urticaria.
        Atarax (hydroxyzine), one of the first non-benzodiazepinic tranquillisers,
        which has given its name to a therapeutic class, the ataraxics;
        Lortab (hydrocodone-paracetamol), an analgesic which reduces sensitivity to
        most types of pain;
        Nootropil (piracetam), a cerebral function regulator and first in the class of
        nootropic agents;




    Further information relating to UCB’s successful product portfolio,
      pipeline and growth strategy is available from their web site at
                          www.ucb-group.com
.
Innovation in development

UCB has a rich Development pipeline and a proven track record in obtaining
product approvals. The wealth of experience and continual pursuit of clinical
excellence fosters an environment seeking innovative strategies to bring medical
solutions to patients, practitioners and payers in a safe and expedient manner.

UCB project teams are encouraged to take time out to think about the disease, the
effect on patients and the underpinning science in order to develop breakthrough
medicines of the future. Imagining the possibilities is the first step towards
innovation.

One team approach

At UCB, the project team extends well beyond Development and encompasses
knowledge from all disciplines across the company. Such broad expertise enables
fully informed and focused development of the product. With an understanding of the
disease, its underlying mechanisms and the impact on the patient UCB are better able
to meet the unmet needs and target our therapies to the right patient.

Global Exploratory Development

The translational medics belong to the Global Exploratory Medicine (GED) group.
GED is a new group in UCB R&D focusing on establishing an optimum knowledge
base for our early projects, in order to increase the likelihood of success in late stage
development. In addition, GED plays a key role in implementing biomarker
programmes in all projects, ensuring early proof of concept for early decision making
and, where applicable, using biomarkers to identify responders, non-responders and
potential safety concerns, thereby aiming at delivering stratified medicine to the
patients. Furthermore, GED drives the implementation of so-called Model Based
Drug Development, a discipline becoming the golden standard to drive decision
making.

UCB are collaborating with world-leading academic institutions within the field of
biomarkers, modelling, experimental therapeutics and the likes, as well as keeping
close contact with regulatory bodies, thereby ensuring they are always at the forefront.

GED's mission is to:

       Ensure optimal use of biomarkers for early decision making, stratification of
       patients in clinical trials and, when applicable, bringing stratified therapies to
       the market
       Support UCB with high quality modelling and simulation support from early
       research to approval and beyond as well as in-depth understanding of the
       Clinical PK of UCB compounds and
       Ensure best-in-class exploratory development programmes with strong focus
       on learning and timely execution and reporting of exploratory phase clinical
       studies
Context of the Role
UCB is a leading research-driven biopharmaceutical company. Using innovative
approaches to drug discovery and development, it has an unmatched combination of
expertise in both chemically derived medicines and biologics. The key features of the
R&D organisation are:

       A dual pipeline approach to Research and Development encompassing
       both New Chemical Entities (NCEs) and New Biological Entities
       (NBEs), allowing UCB to address disease treatment through a range of
       targets and disease pathways.
       A global R&D organisation of 1,700 staff, with major research sites in
       Braine L’Alleud, Belgium and Slough in the UK; and development
       teams based in Atlanta, Braine L’Alleud, Slough, Monheim and Tokyo
       A strategy designed to focus on severe diseases treated by specialists,
       covering two main therapeutic areas: central nervous system and
       inflammation
       World-class scientists harnessing leading and in many cases unique
       technology platforms
       A track record of success through working in partnership with academia
       and other leading drug discovery organisations. UCB R&D actively
       seeks further partnerships through which it can apply its expertise
       (particularly in antibody-based drug discovery and development) in
       order to optimise the delivery of innovative new medicines to the
       market.


The UCB Centre for CNS Innovation (the centre of excellence in CNS) is based
in Braine-l’Alleud, Belgium.
This centre is critical to the further development and continued success of the
pharmaceutical business and has a growing research, discovery and clinical
development function along with an exciting product portfolio. This has created an
exciting and successful drug development pipeline, beyond Keppra, that has included
the development / commercialisation of:


       VimpatTM – approved for use in epilepsy
       Neupro – approved and launched for Parkinson’s disease
       Brivaracetam – phase III development in epilepsy


Additionally, UCB have a healthy drug discovery pipeline with two compounds in
non-clinical development and several neurology-focused projects.
Over recent years the therapeutic strategy of UCB has evolved to reflect the success
that they have enjoyed and to increase the importance of their CNS portfolio, resulting
in significant investment and growth within this group.
Reflecting the growth and strategic importance of the CNS therapeutic area, the
company has recently created a new team focussing on innovative, breakthrough
research – New Targets Biology.
The team will be focused on bringing the very best cellular neurobiology, molecular
biology, and neurotransmission expertise to create an exceptional CNS Biology
group; one that will be focused on world leading research on new drug discovery
targets within the CNS area.
Having enjoyed phenomenal success with Keppra and and expecting even more from
their follow up compounds, and newly launched products within the epilepsy and
Parkinson’s disease areas. UCB are looking to build upon their unique understanding
of Synaptic Vesicle function.
With their focus on the development of a Breakthrough Research group UCB are
looking to dramatically enhance their expertise within a number of different areas,
including:
       Synaptic Vesicle Biology
       Cell Biology
       Molecular Biology and Gene Expression
       Electrophysiology
       Microscopy
UCB have ambitious plans to bring together a group of talented scientists and create a
unique team that will shape the future of the industry within CNS Research.

The role of Director, New Targets Biology will lead this team, by example,
providing the drive, vision, strategy and direction to ensure success and research at
the highest possible standards attainable.

To fill this critical post, we are now seeking an experienced and outstanding cell
biologist, with excellent drug discovery experience and leadership skills. You will
need to be an experienced leader, capable of managing a growing department whilst
also driving the New Targets Biology strategy. You will have a proven track record
within Neuroscience and have worked on an international basis in a leadership
capacity, within global drug discovery and with a strong academic record and
understanding of Synaptic Vesicle Biology.

In addition, the successful candidate will need the strategic and creative thinking
skills, vision and drive to spearhead this exciting initiative within UCB.

Working at the heart of the company’s global R&D organisation, this is a highly
visible, high profile role and requires individuals who will be comfortable working in
the corporate spotlight. In return, the company can offer a stimulating, entrepreneurial
environment, a genuine opportunity to influence the business and a direct and
personal impact on its future success.
The Role

Main Purpose of Position
To provide leadership for New Targets Biology research, through the development of
forward thinking strategic research programs, identifying and developing new
technology and biology target platforms for CNS Biology.

An exciting opportunity for an outstanding cell biologist to have a key role within the
CNS Biology department leading a team of scientists engaged in breakthrough new
targets drug discovery research



Responsibilities
       Demonstrate innovative and opportunistic thinking by taking full
       responsibility for the strategy and direction of the New Targets Biology area
       and group.
       Identify novel target platforms for CNS Biology, working closely with the
       existing CNS research team.

       Lead a team of 7 multi-disciplinary PhD-level scientists engaged in identifying
       and validating new drug discovery targets for CNS diseases.

       As an expert in mechanisms of synaptic neurotransmission, provide a vision
       and strategy for the New Targets Biology team that will lead to the
       identification and validation of innovative new drug targets for CNS diseases.

       Act as an experienced, cross-functional project leader to drive breakthrough
       new target research projects according to well-defined project plans, goals and
       objectives.

       Develop and manage a departmental outsourcing and external collaboration
       and partnership strategy to capture innovative science and technologies.

       Demonstrate excellent communication and networking skills, and be
       recognized as a leader in the field, representing and promoting UCB research
       activities at internal and external scientific meetings and by publishing.

        PhD and postdoctoral experience in cell biology within the neuroscience area
       coupled with an excellent publication record.

       Significant industrial experience of drug discovery with demonstrable success
       within the pharmaceutical / biotech industry required.

       Ensure that the CNS Biology area has the ability to rapidly deliver high
       quality data and information relating to all new targets in discovery research.
Work closely with peers within the CNS Research group to ensure that the
activity of the New Targets Biology area supports the strategy for CNS
research and development.

Guarantee and manage the highest possible standards, quality and reliability
for all biology development.
Ensure that the development of New Targets Biology techniques and
platforms supports the CNS research strategy and prioritisation.
Direct, manage and develop the New Targets Biology team ensuring that you
have the resources, capability, expertise, quality and competence to meet the
needs of the business and the company.
Manage internal and external relationships and third party supplier
relationships.
Ensure that the New Targets Biology area is performing research of a
standard and quality to ensure continuous contributions to the publication
strategy for UCB’s CNS Research.
Present with a high level of credibility and scientific leadership at meetings
and conferences to ensure the high profile of UCB’s New Targets Biology
area.
Person Specification

    In depth knowledge of cellular neuroscience and expertise in neuronal cell
    culture.

    Expertise in synaptic neurotransmission.

    Knowledge and experience of a broad range of biological techniques,
    including molecular biology, analysis of signalling pathways,
    immunocytochemistry, microscopy and neurotransmitter release assays.

    Experience in target identification and validation and design and development
    of compound screening assays.

    Experience in project leadership.

    Experience in managing a team of PhD–level scientists.

    Life Science degree with Ph.D. in Biochemistry or Cell Biology or, preferably,
    Neurobiology.

    Proven high quality scientific contribution in Cell Biology with an emphasis
    on Neuroscience.

    Experienced manager, used to designing, developing and directing CNS
    research and with proven, successful experience in applying in cellular and
    molecular biology within CNS drug discovery.
    Visible track record of success within CNS Drug Discovery, with respected
    publication record to support this.
    Strong problem solving skills, able to resolve complex problems and identify
    creative solutions.
    Quality of experience will be more important than quantity. However, it is
    unlikely that candidates with less than 8 years’ drug discovery and
    development experience within neuroscience / biology research in the industry
    would have sufficient experience for the role.
    An established network and good relationships with research experts and key
    opinion leaders in the CNS area.
    Confidence and professional competence to gain credibility and win respect at
    all levels both within and outside the company.
Person Qualities
    Inspirational leader with an innovative and entrepreneurial spirit.

    Dynamic and passionate about science.

    An ability to challenge and change the way in which we work.

    Well organised with an analytical approach to work.

    Excellent coaching and mentoring skills.

    A team player

    Natural leader, who will lead through example and through respect and
    credibility.
    Able to think globally and strategically.
    Strong prioritisation and project planning skills.
    Mature manager, leader and scientist.
    Ability to think independently and make decisions, having the courage to
    follow instincts and ideas.
    Open to suggestions from others and harbouring an inclusive style.
    Able to adapt easily and take a flexible approach as required.
    Vision, desire and ambition to become a world leader in the field.
    Open and honest with strong, constructive communication and negotiation
    skills.

    Enthusiastic and dynamic, capable of working independently within broad
    objectives without the need for day-to-day supervision.
    Comfortable working in a highly visible, high profile role in an organisation
    with short communication lines and direct access to senior management.
    Highly flexible and adaptable with good analytical and problem solving skills,
    comfortable handling risk and uncertainty and able to make decisions and act
    without necessarily having the full picture.
    A proactive team player with good leadership and mentoring skills,
    comfortable interacting with people at different levels, across functions and
    internationally.
    Fluent in English and a natural communicator, assertive with well developed
    presentation, negotiation and persuasion skills. Spoken French would be
    advantageous.
Package

UCB are able to offer a highly competitive salary, dependent on experience plus
exceptional additional benefits including:

      Competitive base salary (13.92 months)
      Defined contributory pension plan – company contribution 9.15%
      Annual bonus (approximately 20% of gross annual salary, depending on
      performance, but can be significantly greater for high achievers)
      Up to 2500 stock options (negotiable)
      Life insurance – 2-4 x annual remuneration (depending on number of
      dependants)
      Hospitalisation / medical insurance
      Invalidity insurance
      Disability allowance
      Representation Allowance - €198 per month
      Meal vouchers
      Company car – leasing budget €725 per month
      Fully expensed car – insurance, servicing and all fuel
      Conditional non-resident tax status for candidates coming from outside
      Belgium, where appropriate and qualified
             Fiscal advantages
             Relocation / tuition package for children of school age
             Use of external tax advisers and consultants
      Complete relocation package to include:
             Removal of all personal belongings
             Reimbursement of the cost of any physical move
             Relocation services including paid house hunting trip
             Use of external relocation consultants
             Settling in allowance
             Sponsored language lessons
             International school fees

								
To top